Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS

Glatiramer acetate (GA), a synthetic copolymer, is a frequently used first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Probable autoimmune hepatotoxicity during GA treatment has been reported,1–4 but GA hepatotoxicity in the absence of positive autoimmune markers has not previously been described. Here, we report GA-induced hepatotoxicity in a pediatric patient with multiple sclerosis (MS). Acknowledgement: The authors thank Lynn MacMillan for assistance in acquiring patient data for this report.